Related Experiment Video

Updated: May 14, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Decitabine monotherapy for pediatric myelodysplastic syndrome: A case report

Zhimin Fan1, Nengwen Xu1, Alicia Senin2

  • 1Department of Hematology, Lishui Central Hospital, Lishui, Zhejiang 323400, P.R. China.

Experimental and Therapeutic Medicine
|May 13, 2026
PubMed

Insights

Pediatric myelodysplastic syndrome (MDS), often refractory cytopenia of childhood (RCC), has limited treatment options. Decitabine monotherapy stabilized disease in a child ineligible for stem cell transplant or immunosuppressive therapy, suggesting a new treatment possibility.

Area of Science:

  • Pediatric Hematology
  • Oncology
  • Stem Cell Transplantation

Background:

  • Myelodysplastic syndrome (MDS) in children is rare, typically presenting as refractory cytopenia of childhood (RCC).
  • Current management for pediatric MDS includes chemotherapy, immunosuppressive therapy (IST), and allogeneic hematopoietic stem cell transplantation (HSCT).
  • Limited therapeutic data exists for RCC patients unsuitable for HSCT or IST.

Keywords:
decitabinepediatric myelodysplastic syndromerefractory cytopenia in childhood

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...